7411 results for "canc*"

in 21.65 milliseconds.

• Multi-omic signatures in multiple myeloma

  Multiple myeloma (MM) is a genetically and clinically heterogeneous plasma-cell malignancy. Quadruplet therapy, combining anti-CD38 antibodies, immunomodulatory drugs, proteasome inhibitors, and dexamethasone, is now the standard induction treatment for newly diagnosed multiple myeloma (NDMM). To gain a comprehensive view of molecular changes in MM and their association with treatment response in this new standard care, we performed a multi-omic study of 423 NDMM from the MIDAS trial.

  Study EGAS50000001573

• Dataset of scRNAseq from 56 CRC, treatment-naive and post-chemotherapy

  The dataset includes FASTQ source files of scRNA-seq for 56 CRC patients, sequenced with Illumina 10x platform. All patients were diagnosed with colorectal cancer between 2014 and 2022 at the Gustave Roussy Institute. Cohort includes 32 samples from untreated patients and 24 samples from patients who received chemotherapy. Chemotherapy included FOLFOX or FOLFIRI as first line, in some cases in combination with anti-VEGF or anti-EGRF drugs (avastin, bevacizumab or cetuximab) as the second and third lines. The post-treatment cohort included 18 responders (partial response, stable disease and complete response) and 6 progressors (progressive disease).

  Dataset EGAD50000001218

• Asan Medical Center Data Access Committee

  This Data Access Committee is responsible for reviewing and approving data access requests for human genomic and clinical datasets deposited at the EGA by Asan Medical Center, in order to protect the sensitive information of patients. The committee oversees a range of data types, including sequencing, variant profiling, and transcriptomic data across multiple cancer types and research projects. Data access requests require an approved ethical research plan and are limited to legitimate biomedical research use in accordance with the terms of the associated Data Access Agreement.

  Dac EGAC50000000439

• The evolving genomic landscape of circulating tumor DNA represents an early predictor of immunotherapy response in lung cancer

  Circulating tumor DNA (ctDNA) analyses are informative as an early indicator of immunotherapy response in advanced non-small cell lung cancer (NSCLC), however the clinical role of ctDNA molecular response requires further validation. As part of a prospective clinical protocol (NCT05995821), we performed ctDNA (n=328) and matched white blood cell DNA (WBC; n=109) targeted error-correction sequencing from 109 patients with advanced/metastatic NSCLC who received anti-PD-(L)1 as monotherapy or in combination. Following variant cellular origin resolution, landmark molecular response (mR) was defined as undetectable ctDNA within 3-9 weeks of treatment initiation. Among 2,818 plasma variants, 23% were clonal haematopoiesis-related, which confounded driver gene associations with clinical outcomes and molecular responses. Implementing a tumor-naïve WBC DNA-informed approach increased the number of evaluable cases while maintaining the overall accuracy of landmark ctDNA molecular responses. Pre-treatment ctDNA burden but not blood tumor mutation burden predicted survival. A significant enrichment in landmark ctDNA mR was noted among patients with progression-free survival (PFS) ≥6 months with immunotherapy (p=2.5e-05) and chemo-immunotherapy (p=0.02). Patients in the landmark mR group attained longer progression-free (p=1.6e-06) and overall survival (p=2.5e-05) compared to those with molecular progression. Our findings indicate that landmark ctDNA molecular response provides a real-time and accurate approach for monitoring immunotherapy clinical outcomes. Although not currently validated for regulatory use, these findings demonstrate the potential utility of ctDNA as an early endpoint in clinical trials.

  Study EGAS50000001957

• Dataset for "The evolving genomic landscape of circulating tumor DNA represents an early predictor of immunotherapy response in lung cancer"

  Dataset for the study "The evolving genomic landscape of circulating tumor DNA represents an early predictor of immunotherapy response in lung cancer". This study has 437 samples and the corresponding bam from TEC-seq

  Dataset EGAD50000002837

• Data access committee for study: "Landmark ctDNA molecular response represents an early predictor of immunotherapy outcomes in lung cancer"

  This is the Data Access committee that regulates access to the sequence data for the study: "Landmark ctDNA molecular response represents an early predictor of immunotherapy outcomes in lung cancer".

  Dac EGAC50000000787

• Wellcome LEAP TNBC cohort raw sequencing data

  This study contains controlled-access raw sequencing data from the retrospective Wellcome LEAP triple-negative breast cancer cohort. The data include human patient-derived single-nucleus RNA-seq and 10x Visium spatial transcriptomics generated from pre- and post-treatment tumour samples. The first dataset linked to this study supports the Victori et al. Cell Reports Medicine manuscript and includes raw FASTQ files from the relevant sequencing runs. Because some snRNA-seq libraries were generated from multiplexed pools, some raw FASTQ files may include additional co-multiplexed LEAP samples beyond those directly analysed in that manuscript. Access is controlled through the appropriate LEAP Data Access Committee and policy.

  Study EGAS50000001956

• Wellcome LEAP TNBC Data Access Committee

  Data Access Committee for controlled-access human patient-derived sequencing data from the Wellcome LEAP triple-negative breast cancer study

  Dac EGAC50000001072

• Amplicon-based sequencing of drug resistant lung cancer cell lines (2017-07-05)

  A EGFR mutant NSCLC cell line which is sensitive to AZD9291 inhibition was mutagenised with the chemical mutagen ENU and then drug selected using a AZD9291. Single cell derived colonies were then manually picked and expanded in drug. Resistance was confirmed in a 14 day assay and DNA was collected. These then underwent targeted amplicon-based sequencing to confirm candidate resistance effectors hypothesised from currently available literature. This dataset contains all the data available for this study on 2017-07-05.

  Dataset EGAD00001003425

• Exome and Transcriptome for pan-cancer gene-drug analysis

  Total of 584 tumor specimens and/or patient-derived cells across 14 cancer types were subjected for whole-exome/targeted-exome and/or whole-transcriptome sequencing.

  Dataset EGAD00001003441